Mesoblast (ASX:MSB) share price jumps 12% on FDA update

On the back of a tough week, Mesoblast has some positive news to celebrate today.

| More on:
Happy woman cheering with hands in air after Mesoblast share price soars

Image source: Getty Images

The Mesoblast Limited (ASX: MSB) share price is soaring today on the back of a clinical trial update.

In morning trade, the company’s shares are trading at $1.495, up 12%.

Mesoblast is working on regenerative medicines for serious inflammatory conditions including chronic back pain.

What is impacting the share price today?

Investors are responding to feedback the company received from the FDA’s Office of Tissues and Advanced Therapies (OTAT).

The company is trialling the use of its flagship rexlemestrocel-L product in the treatment of chronic back pain.

Mesoblast will be conducting another phase 3 trial based on OTAT’s review of initial trial data.

The regulatory body agrees with Mesoblast’s plan to use pain reduction at 12 months as the key endpoint for this pending trial.

Opioid use reduction and functional improvement will be secondary endpoints for the trial.

If the trial blasts ahead to EU regulatory approval, the company will be eligible for multi-million dollar payments.

Mesoblast said it could receive a US$112.5 million payout ahead of the product launch from partner company Grünenthal if the approval goes ahead.

The company predicts milestone payments could reach a mammoth US$1 billion depending on trial results and patient uptake.

Mesoblast sees the potential to market its product as a solution to excessive use of opioids in the US.

What else is happening at Mesoblast

The Mesoblast share price crashed on Tuesday after pharmaceutical giant Novartis terminated an agreement with the company to use remestemcel-L to treat acute respiratory distress syndrome (ARDS) from COVID-19.

However, the company maintains that it remains highly focused on bringing this product to the market to help patients impacted by this condition.

Mesoblast still sees potential to pursue emergency use authorisation of remestemcel-L based on clinical results.

Mesoblast share price snapshot

In the past 12 months, the Mesoblast share price has plunged 60% and dived nearly 34% in the year to date.

Shares in the company have slipped 15% in the past month and 22% in the past week.

Mesoblast has a market capitalisation of roughly $967 million based on the current share price.

Should you invest $1,000 in Mesoblast right now?

Before you consider Mesoblast, you'll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of January 13th 2022

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today
Healthcare Shares

Imugene share price surges 18% to lead the ASX 200 on Thursday

What's behind the meteoric gain for this ASX 200 healthcare stock today?

Read more »

Rising arrow on a blue graph symbolising a rising share price.
Healthcare Shares

Next Science shares defy ASX market slump to surge 8%

Next Science shares are set to finish Thursday's trading session on a high note.

Read more »

Team celebrating corporate success screaming with joy.
Healthcare Shares

How is the Polynovo share price managing to push higher today?

Polynovo shares are defying the broader ASX market on Thursday.

Read more »

An unhappy man in a suit sits at his desk with his arms crossed staring the his laptop screen as the Mesoblast share price falls
Healthcare Shares

Mesoblast share price dips amid latest class action news

The company is being taken to court by another unhappy shareholder.

Read more »

A smiling woman looks at her computer laptop in her home with warm lights in the background feeling happy to see the EMvision share price rising
Healthcare Shares

EMvision share price rockets 11% on $5 million pay day

Shares in the Australian medical device company shot higher today.

Read more »

retirement investing represented by older investor looking concerned at computer screen
Healthcare Shares

Why is the Medibank share price struggling to gain ground in May?

We check what's going on with shares in the private health insurer.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Healthcare Shares

Here’s why the Imugene share price just got a boost

Imugene's latest announcement is rallying up investors.

Read more »

A man wearing a mask punches the air with joy after getting a negative COVID result on a rapid antigen test.
Healthcare Shares

Why the AnteoTech share price is rocketing 33% today

What did AnteoTech update the ASX with?

Read more »